Hormone Resistant Prostate Cancer Withdrawn Phase 2 Trials for Durvalumab (DB11714)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02966587Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment